Allergan, Inc.

Pharmaunternehmen14 erfasste Produkte

erfasste Produkte

339.204

Meldungen insgesamt

dokumentierte Rückrufe

44,3%

schwerwiegend insgesamt

Produkte

14 von 14 angezeigt

Produkt	Zugelassen	Meldungen ↓	Top-Signal	Rückrufe
prednisolone —	1955	188.016	Cytomegalievirus-Infektion	33
onabotulinumtoxina —	1991	75.403	Mehrfachverwendung eines Einwegprodukts	0
linaclotide —	2012	25.697	Blähungen	1
prednisolone acetate —	1955	10.056	Endophthalmitis	8
cariprazine —	2015	8.903	Akathisie	1
brimonidine tartrate, timolol maleate —	—	6.551	Erhöhter Augeninnendruck	5
milnacipran hydrochloride —	2009	5.952	Fibromyalgie	0
ubrogepant —	2019	5.632	Migräne	0
norethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate —	—	3.150	Ausbleiben der Menstruation	0
eluxadoline —	2015	2.902	Kontraindiziertes Medikament verschrieben	0
carboxymethylcellulose sodium and glycerin —	—	2.372	Sklerale Hyperämie	0
levomilnacipran hydrochloride —	2013	1.881	Überlappungssyndrom	0
gatifloxacin —	2003	1.747	Toxisches anteriores Segment-Syndrom	13
carboxymethylcellulose sodium, glycerin, and polysorbate 80 —	—	942	Schmerzen am Augenlid	0

Rückrufhistorie · 39 dokumentiert

Datum	Klasse	Grund	Firma
18. Mai 2026	III	Failed Stability Specifications	AbbVie Inc.
26. Apr. 2023	II	CGMP Deviations: Firm went out of business and could no longer continue stability studies.	Akorn, Inc.
7. Okt. 2022	II	Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.	Pharmacy Plus, Inc. dba Vital Care Compounder
1. Aug. 2022	II	Defective Container: Product has incomplete induction seals.	Akorn, Inc
13. Apr. 2022	II	cGMP deviations: Temperature abuse	Mckesson Medical-Surgical Inc. Corporate Office
22. Dez. 2021	III	Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.	Lupin Pharmaceuticals Inc.
20. Okt. 2021	III	Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.	Lupin Pharmaceuticals Inc.
15. März 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
15. März 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
5. Juni 2020	III	Discoloration: Out of Specification (OOS) result for APHA Color Test.	Akorn, Inc.
17. Okt. 2019	III	Labeling: Incorrect or missing package insert.	Sandoz Inc
23. Sept. 2019	II	Failed Impurities/Degradation Specifications - failed specs for Prednisolone Impurity 14	Morton Grove Pharmaceuticals, Inc.
6. Sept. 2019	III	Failed Impurities/Degradation Specifications:OOS for unknown impurity.	Mylan Pharmaceuticals Inc.
11. Juli 2019	III	Labeling: Missing label; Product complaints reported missing bottle label.	Lupin Pharmaceuticals Inc.
17. Dez. 2018	II	Lack of sterility assurance.	Promise Pharmacy, LLC
17. Dez. 2018	II	Lack of sterility assurance.	Promise Pharmacy, LLC
17. Dez. 2018	II	Lack of sterility assurance.	Promise Pharmacy, LLC
17. Dez. 2018	II	Lack of sterility assurance.	Promise Pharmacy, LLC
17. Dez. 2018	II	Lack of sterility assurance.	Promise Pharmacy, LLC
18. Okt. 2018	III	Presence of precipitate	Promise Pharmacy LLC
24. Juli 2018	II	Defective Container: Tamper Evident foil seal not completely intact.	Morton Grove Pharmaceuticals, Inc.
30. Apr. 2018	II	CGMP Deviations	Mylan Pharmaceuticals Inc.
30. Apr. 2018	II	CGMP Deviations	Mylan Pharmaceuticals Inc.
30. Apr. 2018	II	CGMP Deviations	Mylan Pharmaceuticals Inc.
16. Nov. 2017	II	Labeling: Incorrect or Missing Lot and/or Exp Date: Beyond Use Date (BUD) exceed the BUD/EXP of at least one ingredient used to make final product.	KRS Global Biotechnology, Inc
1. Mai 2017	II	Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for impurities.	Allergan Sales, LLC
28. März 2017	III	Failed Stability Specifications	Teva Pharmaceuticals USA
20. Sept. 2016	II	Lack of Assurance of Sterility; all compounded products within expiry produced using recalled filters	Leiter's Compounding
12. Sept. 2015	II	Lack of Assurance of Sterility; The firm is recalling all sterile preparations that are within expiry due to deficient practices which may have an impact on sterility assurance.	US Compounding Inc
24. Aug. 2015	II	Presence of Particulate Matter: Due to customer complaints of small black particles, identified as part of the ointment tube cap, generated by the action of unscrewing the cap from the aluminum tube and potentially introducing the particle into the product.	Allergan Sales, LLC
14. Nov. 2014	II	Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.	Attix Pharmaceuticals
14. Nov. 2014	II	Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.	Attix Pharmaceuticals
14. Nov. 2014	II	Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.	Attix Pharmaceuticals
14. Nov. 2014	II	Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.	Attix Pharmaceuticals
6. Okt. 2014	II	Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.	Oregon Compounding Centers, Inc. dba Creative Compounds
27. Aug. 2014	II	Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of all compounded sterile preparations within expiry. The recall is being initiated in connection with a recent FDA inspection due to observations associated with certain quality control procedures that present a risk to sterility assurance.	Martin Avenue Pharmacy, Inc.
19. Okt. 2013	II	Lack of Assurance of Sterility: All unexpired sterile compounded human and veterinary products are being recalled because they were compounded in the same environment and under the same practices as another product found to be non-sterile and therefore sterility cannot be assured.	Specialty Medicine Compounding Pharmacy
2. Juli 2013	II	Labeling: Label Mixup; prednisoLONE, Tablet, 5 mg may be potentially mislabeled as ASPIRIN/ER DIPYRIDAMOLE, Capsule, 25 mg/200 mg, NDC 00597000160, Pedigree: W003644, EXP: 8/24/2013.	Aidapak Services, LLC
21. Mai 2012	II	Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012. FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.	Franck's Lab Inc., d.b.a. Franck's Compounding Lab

Klasse I = begründete Wahrscheinlichkeit schwerwiegender Schäden · Klasse II = vorübergehend oder reversibel · Klasse III = Schaden unwahrscheinlich.

Registrierungsstatus

Einige Produkte von Allergan, Inc. sind nicht für die Anwendung am Menschen FDA-registriert. Für nicht registrierte Substanzen (Peptide, SARMs ohne Humanzulassung) existiert kein legitimer Anbieter für die Anwendung am Menschen. Das Fehlen eines Bezugswegs ist die Sicherheitsinformation.